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Received October 20, 2015; accepted February 2, 2016AbstractBackground: Atrial fibrillation (AF) is associated with an increased risk of dementia. However, limited data are available on the predictors of
dementia in patients with AF. This study aimed to evaluate whether the CHADS2 score could be a useful tool for risk stratification with regard to
dementia occurrence among patients with AF.
Methods: AF patients were identified from the National Health Insurance sampling database, which has accumulated a total of 1,000,000
participants since 2000. After excluding patients diagnosed with dementia prior to the index day of enrollment, CHADS2 score was measured to
investigate its association with the occurrence of dementia, including vascular dementia and Alzheimer's disease.
Results: During the mean follow-up period of 3.71 ± 2.78 years, 1135 dementia cases (7.36%) were identified, including 241 cases of vascular
dementia and 894 cases of Alzheimer's disease. In multivariate analysis, an increase of 1 point in the CHADS2 score was independently
associated with a 54% increase in the risk of vascular dementia (hazard ratio ¼ 1.54; 95% confidence interval, 1.41e1.69; p < 0.001) and a 40%
increase in Alzheimer's disease (hazard ratio ¼ 1.40; 95% confidence interval, 1.34e1.46; p < 0.001).
Conclusion: CHADS2 score is a useful predictor for the development of vascular dementia as well as Alzheimer's disease in patients with AF.
Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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Evidence increasingly suggests that atrial fibrillation (AF)
is associated with late-life dementia.1 This strong association
is not only seen in vascular dementia, but also in Alzheimer's
disease (AD).2 It has been reported that AF may be associated
with higher risk of cognitive function impairment and maysevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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explanation is the increased incidence of stroke. Ott et al3 have
demonstrated that even among AF patients without stroke, AF
is still associated with dementia and AD. Both vascular de-
mentia and AD had been reported to be associated with AF.
CHADS2 has been reported to be of use for risk stratification
regarding stroke recurrence among patients with AF4 and has
also been reported to predict AF recurrence after ablation and
predict AF complications among AF patients.5,6 However,
information about the use of CHADS2 score to predict de-
mentia, including vascular dementia and AD, is limited.
Therefore, we conducted a large-scale, nationwide,
population-based cohort study to investigate the correlation
between the CHADS2 score and the future risk of vascular
dementia or AD, and whether it could be a useful tool to
stratify risk in AF patients.
2. Methods2.1. Study population and data sourceThe National Health Insurance program has enrolled nearly
all the inhabitants of Taiwan since 1995. As described in our
previous study,7,8 the National Health Research Institute
(NHRI) in Miaoli, Taiwan, manages the complete National
Health Insurance claims database, and makes datasets avail-
able to applicants for medical research purposes. In each
dataset, the patient's original identification number has been
encrypted to protect privacy, using a consistent encrypting
procedure, thus allowing linkage of claims belonging to the
same patient within the NHRI database.
Patients with AF or atrial flutter were identified according
to ICD coding (International Classification of Diseases, 9th
Revision, Clinical Modification code 427.31, 427.32) from a
cohort dataset of 1 million individuals sampled from the NHRI
database between January 1, 2000 and December 31, 2009.
Diagnosis of AF was identified using coding by qualified
cardiologists for the purpose of insurance claims. The date of
AF occurrence was set as the date when the diagnosis first
presented in the dataset. To clearly demonstrate the relation-
ship between AF and occurrence of dementia, AF with pre-
vious dementia diagnosis prior to the index date of enrollment
were excluded in this study. A similar definition for AF has
been described in our previous works.7e102.2. Identification of dementiaTo investigate the association between AF and dementia,
vascular dementia and AD were analyzed separately. The
diagnosis of dementia was identified using coding by a qual-
ified neurologist, either presented once in the diagnosis of
hospitalization or presented at least two times in outpatient
clinic visits. The ultimate diagnosis should be correct due to
the insurance claim purposes. Vascular dementia was defined
as the presence of arteriosclerotic dementia (ICD 9: 290.4,
290.40, 290.41, 290.42, 290.43), following the diagnosis of
newly developed stroke (ICD 9: 433.xxe438.xx), andundergoing at least one image study (computed tomography,
brain magnetic resonance imaging) after enrollment. AD was
identified with the ICD code of Alzheimer's disease (331.0). In
addition, senile dementia (290.0, 290.2, 290.20, 290.21, 290.3)
without stroke or other significant secondary cause11e13 of
cognitive impairment was also identified as AD in this study.
Similar methods for the identification of AD were applied in
our previous works.8,10 All patients were followed up until
December 31, 2009, or until the presence of either type of
dementia was noted.2.3. CHADS2 score and study variablesIn addition to age and sex, we identified the following
comorbidities for each patient upon initiation of the study:
hypertension (401.xxe405.xx), diabetes mellitus (250.xx),
coronary artery disease (410.xxe414.xx), stroke
(430.xxe438.xx), chronic kidney disease (580.xxe587.xx),
congestive heart failure (428.xx), peripheral artery disease
(440.xxe444.xx), chronic obstructive pulmonary disease
(490.xxe496.xx), and valvular heart disease (424.xx). The
ICD codes of the comorbidities were summarized in Table S1.
Variables that are components of the CHADS2 score were
retrieved. The CHADS2 score is a risk stratification score that
ranges from 0 to 6 and is calculated as follows: congestive
heart failure (1 point), hypertension (1 point), age  75 years
(1 point), diabetes mellitus (1 point), and stroke (2 points). The
CHADS2 score was calculated for each participant at study
entry.4
Concomitant medication usage (aspirin, ticlopidine, clopi-
dogrel, warfarin, angiotensin-converting enzyme inhibitor,
angiotensin receptor blocker, calcium channel blocker, thia-
zide, statins) was identified and classified according to the
National Drug Code and the Anatomic Therapeutic Chemical
code, an internationally accepted drug classification system
coordinated by the World Health Organization Collaborating
Center for Drug Statistics Methodology. Patients must have
received a prescription for at least 90 days during the obser-
vation period in order to be identified as a medical user. This
study was exempt from full review by the Institutional Review
Board of Taipei Veterans General Hospital, Taipei, Taiwan,
because the selected dataset consisted of deidentified sec-
ondary data released to the public for research purposes.2.4. Statistical analysisWe used Microsoft SQL Server 2005 (Microsoft Corpora-
tion, Redmond, Wash) to manage and compute the data. Sta-
tistical analysis was performed using SPSS software (version
18.0; SPSS Inc., Chicago, IL, USA). Ordinal and categorical
data were expressed as the frequency (%), and continuous data
were expressed as mean ± standard deviation. The categorical
data were compared between the two cohorts with Chi-square
test and Yates' correction or Fisher's exact test. Continuous
data among the different groups of patients were compared
using unpaired Student t tests. Survival curves were assessed
by the KaplaneMeier method, and survival among groups was
Fig. 1. Flowchart of patient enrollment. AF ¼ atrial fibrillation; AFL ¼ atrial
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(AUC), or C-statistics, was used as a measure of the predictive
accuracy of CHADS2 score. The criterion value of the scoring
system was determined by the Youden index,
sensitivity þ specificity 1. To assess the independent effects
of the CHADS2 score, we conducted Cox proportional hazard
regression models simultaneously adjusting for sex and
comorbidities not included in the calculation of the CHADS2
score (coronary artery disease, chronic kidney disease), as well
as concomitant medication use (aspirin, ticlopidine, clopi-
dogrel, warfarin, angiotensin-converting enzyme inhibitor,
angiotensin receptor blocker, calcium channel blocker, thia-
zide, statins) in the model. A two-sided p value < 0.05 was
considered to indicate statistical significance.
3. Results
flutter.3.1. Patient characteristicsA total of 15,430 patients with AF or atrial flutter without
previously diagnosed dementia were enrolled in this study.
The baseline characteristics of study participants are shown in
Table 1. The incidence of hypertension, diabetes, history of
stroke, and congestive heart failure were 77%, 36.3%, 38.2%,
and 42.7%, respectively, and the mean CHADS2 score was
2.73 ± 1.63. During the mean follow-up of 3.71 ± 2.78 years,
1135 cases of dementia (7.36%) were diagnosed, with 241
cases and 894 cases of vascular dementia and AD, respectively
(Fig. 1). AF patients with dementia were older (77.37 ± 8.01Table 1
Baseline characteristics of patients with atrial fibrillation.
n ¼ 15,430




Diabetes mellitus 5595 (36.3)
Congestive heart failure 6585 (42.7)
Coronary artery disease 9827 (63.7)
Previous stroke/TIA 5898 (38.2)
Peripheral artery disease 2241 (14.5)
Chronic kidney disease 3522 (22.8)
COPD 8748 (56.7)











CHADS2 score* 2.73 ± 1.63
Data are presented as n (%) or mean ± standard deviation.
ACEI ¼ angiotensin-converting enzyme inhibitors;
ARB ¼ angiotensin II receptor blockers; CCB ¼ calcium channel
blocker; COPD ¼ chronic obstructive pulmonary disease;
TIA ¼ transient ischemic attack.vs. 69.54 ± 13.1%, p < 0.001) and had a higher incidence of
hypertension, coronary artery disease, history of stroke/tran-
sient ischemic attack (TIA), and chronic kidney disease
(Table 2). In addition to having more comorbidities, patients
with dementia were also taking more medications including
antiplatelet agents, antihypertensive agents, and statins.
Compared to patients developing AD, a higher percentage of
AF patients developing vascular dementia were using anti-
platelet agents, anticoagulant agents, and statins, and had
higher CHADS2 scores (3.6 ± 1.4 vs. 3.39 ± 1.45, p ¼ 0.043;
Table 3).Table 2






Age (y)a 77.37 ± 8.01 69.54 ± 13.1 <0.001
Male (%) 558 (49.2) 8186 (57.3) <0.001
Medical history
Hypertension 979 (86.3) 10,898 (76.2) <0.001
Diabetes mellitus 459 (40.4) 5136 (35.9) 0.002
Congestive heart failure 501 (44.1) 6084 (42.6) 0.300
Coronary artery disease 793 (69.9) 9034 (63.2) <0.001
Previous stroke/TIA 609 (53.7) 5289 (37.0) <0.001
Peripheral artery disease 185 (16.3) 2056 (14.4) 0.078
Chronic kidney disease 300 (26.4) 3222 (22.5) 0.003
COPD 664 (58.5) 8084 (56.6) 0.202
Valvular heart disease 249 (21.9) 3378 (23.6) 0.196
Medications
Aspirin 912 (62.0) 6379 (44.6) <0.001
Licodin 97 (6.6) 480 (3.4) <0.001
Clopidogrel, 197 (13.4) 1506 (10.5) 0.001
Warfarin 262 (17.8) 2324 (16.3) 0.123
ACEI 534 (36.3) 3342 (23.4) <0.001
ARB 542 (36.9) 4796 (33.6) 0.010
CCB 959 (65.2) 7141 (50.0) <0.001
Thiazide 467 (31.8) 3436 (24.0) <0.001
Statins 195 (13.3) 2345 (16.4) 0.002
CHADS2 score 3.43 ± 1.44 2.68 ± 1.63 <0.001
Data are presented as n (%) or mean ± standard deviation.
ACEI ¼ angiotensin-converting enzyme inhibitors; ARB ¼ angiotensin II
receptor blockers; CCB ¼ calcium channel blocker; COPD ¼ chronic
obstructive pulmonary disease; TIA ¼ transient ischemic attack.
Table 3









Age (y)a 76.95 ± 7.98 77.49 ± 8.02 0.351
Male (%) 120 (49.8) 438 (49.0) 0.826
Medical history
Hypertension 205 (85.1) 774 (86.6) 0.544
Diabetes mellitus 100 (41.5) 359 (40.2) 0.707
Congestive heart failure 101 (41.9) 400 (44.7) 0.432
Coronary artery disease 166 (68.9) 627 (70.1) 0.706
Previous stroke/TIA 153 (63.5) 456 (51.0) 0.001
Peripheral artery disease 38 (15.8) 147 (16.4) 0.801
Chronic kidney disease 70 (29.0) 230 (25.7) 0.300
COPD 131 (54.4) 533 (59.6) 0.141
Valvular heart disease 55 (22.8) 194 (21.7) 0.709
Medications
Aspirin 174 (72.2) 529 (59.2) <0.001
Licodin 23 (9.5) 53 (5.9) 0.046
Clopidogrel 51 (21.2) 108 (12.1) <0.001
Warfarin 59 (24.5) 146 (16.3) 0.004
ACEI 89 (36.9) 325 (36.4) 0.869
ARB 100 (41.5) 324 (36.2) 0.135
CCB 148 (61.4) 592 (66.2) 0.164
Thiazide 80 (33.2) 297 (33.2) 0.994
Statins 48 (19.9) 111 (12.4) 0.003
CHADS2 score
a 3.60 ± 1.40 3.39 ± 1.45 0.043
Data are presented as n (%) or mean ± standard deviation.
ACEI ¼ angiotensin-converting enzyme inhibitors; ARB ¼ angiotensin II
receptor blockers; CCB ¼ calcium channel blocker; COPD ¼ chronic
obstructive pulmonary disease; TIA ¼ transient ischemic attack.
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developing dementia and CHADS2 score among AF patients,
the incidence of dementia development was analyzedFig. 2. The incidence of dementia continuously correlates with CHADS2
scores among patients with atrial fibrillation (AF).according to an increasing CHADS2 score. Fig. 2 shows the
incidence of developing dementia to be significantly associ-
ated with CHADS2 score. The incidence of dementia was
1.98% per 100 person-years in the AF population. As the
CHADS2 score increased, the incidence of dementia
augmented gradually, which was up to 4.86% for patients with
a 6-point CHADS2 score (Table 4).
Using KaplaneMeier analyses has clearly shown that the
risk of developing dementia is associated with increasing
CHADS2 score over time (Fig. 3), regardless of whether pa-
tients developed vascular dementia (log rank p < 0.001) or AD
(log rank p < 0.001), indicating that increasing CHADS2 score
correlated with the risk of developing dementia in AF patients.
Table 5 shows the C-statistics for the CHADS2 score in
predicting the incidence of dementia and its subtypes. As a
predictor for dementia, CHADS2 score showed acceptable
sensitivity, but with relatively low specificity. Unsurprisingly,
the discriminatory performance of CHADS2 score was better
in predicting vascular dementia than predicting AD.3.3. Hazard analysis of individual factors of CHADS2
scoreThe Cox proportional hazard analysis revealed strong
positive correlations between different types of dementia,
CHADS2 score, and each individual factor of the CHADS2
score (Table 6). Even after adjustment of variables and
comorbidities including sex, coronary artery disease, chronic
kidney disease, and use of aspirin, licodin, clopidogrel,
ACEI, ARB, CCB, thiazide, or statins, the CHADS2 score
remained independently associated with the development of
all-cause dementia [hazard ratio (HR) ¼ 1.43; 95% confi-
dence interval (CI), 1.37e1.49; p < 0.001], vascular de-
mentia (HR ¼ 1.54; 95% CI, 1.41e1.69; p < 0.001), and AD
(HR ¼ 1.40; 95% CI, 1.34e1.46; p < 0.001). Subsequent
analysis of the hazard ratio of the CHADS2 score in patients
with different comobidities still showed similar results (Figs.
S1eS3). (HTN ¼ hypertension, DM ¼ diabetes mellitus,
CKD ¼ chronic kidney disease, CHF ¼ congestive heart
failure, COPD ¼ chronic obstructive pulmonary disease,
VHD ¼ vavular heart disease, CAD ¼coronary artery
disease).Table 4











0 1287 14 6342 0.22
1 2731 109 12,583 0.87
2 3192 181 12,981 1.39
3 3080 275 10,679 2.58
4 2578 257 8177 3.14
5 1846 224 5011 4.47
6 716 75 1544 4.86
Total 15,430 1135 57,316 1.98
Fig. 3. KaplaneMeier estimates of time to developing (A) all-cause dementia, (B) vascular dementia, and (C) Alzheimer's disease by CHADS2 scores.
Table 5
The C-statistic of CHARS2 score in prediction of the incidence of dementia,
vascular dementia, and Alzheimer's disease.
AUC Criterion
value
Sensitivity (%) Specificity (%)
Dementia 0.633 >2 73.22 48.31
Vascular dementia 0.656 >2 77.59 47.11
Alzheimer's disease 0.622 >2 72.04 47.88
AUC ¼ area under ROC curve.
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It has been reported that AF may increase the risk of
developing dementia.8 Our current study demonstrated that the
CHADS2 score is a useful parameter for predicting future risk
of development of vascular dementia as well as AD, providing
useful information to categorize AF patients at risk of devel-
oping dementia in the future.
More and more evidence suggests that AF may be a risk
factor, or may even contribute directly to the development of
dementia.1,14 In addition to being associated with an approx-
imately five-fold increase in the risk of clinical stroke,15 AF
has also been associated with more severe ischemic strokes
and longer TIAs than emboli from carotid disease.16,17 It is not
difficult to connect AF with post-stroke dementia and all other
types of vascular dementia. Much to our interest, AF is not
only significantly related to vascular dementia, but also to
AD.18 A single cross-sectional study in 1997,3 which included
6584 participants, showed an association between AF and
dementia [odds ratio (OR) ¼ 2.3; 95% CI, 1.4e3.7]. TheTable 6
Cox proportional hazard analysis for the predictors of all-cause dementia, vascula
Variable All-cause dementia
HR (95% CI) p HR (95%
Age >75 y 3.75 (3.32e4.24) <0.001 3.65 (2.8
HTN 2.29 (1.94e2.72) <0.001 2.08 (1.4
DM 1.44 (1.28e1.63) <0.001 1.51 (1.1
CHF 1.22 (1.08e1.37) 0.001 1.11 (0.8
Stroke 2.39 (2.13e2.69) <0.001 3.61 (2.7
CHADS2
score
1.48 (1.43e1.54) <0.001 1.59 (1.4
1.43 (1.37e1.49)a <0.001a 1.54 (1.4
ACEI ¼ angiotensin-converting enzyme inhibitors; ARB ¼ angiotensin II recepto
CHF ¼ congestive heart failure; CI ¼ confidence interval; CKD ¼ chronic kidney
a Adjusted for sex, CAD, CKD, and medicines (include aspirin, licodin, clopidostrongest association was found not for vascular dementia, but
rather for AD with cerebrovascular disease (OR ¼ 4.1; 95%
CI, 1.7e9.7). An association was also present between AF and
pure AD (OR ¼ 1.8; 95% CI, 1.7e9.7). Similar results have
also been found in recent longitudinal studies and meta-ana-
lyses.19,20 In a meta-analysis that included 21 observational
studies,20 AF was significantly associated with a higher risk
for cognitive impairment in patients with a history of stroke
[relative risk (RR) ¼ 2.70; 95% CI, 1.82e4.00] than in those
without (RR ¼ 1.34; 95% CI, 1.13e1.58). Additionally, an
observational study also found that warfarin use may reduce
the incidence of dementia in AF patients.21 Bunch et al22 re-
ported that patients who underwent AF ablation had a lower
risk of AD than those who did not, suggesting a close rela-
tionship between dementia and AF, and that treatment for AF
may potentially reduce the risk of dementia.
Several mechanisms have been proposed to explain the
relationship between AF and vascular dementia. First, AF
leads to incomplete draining of the left atrium and thus
increased intracardiac thrombus formation, in turn increasing
the risk of stroke and systemic embolism. In addition to
stroke, patients with AF also suffer subclinical silent cerebral
emboli.23 Evidence of silent brain infarction on brain mag-
netic resonance imaging more than doubles the risk of de-
mentia as noted in one neuropsychological study.24 Second,
AF increases the beat-to-beat variation of heart rate and
cardiac output, resulting in cerebral hypoperfusion.25 Other
possible mechanisms include the hypercoagulability21 and
proinflammatory state presenting with AF.26,27 Vascular andr dementia, and Alzheimer's disease.
Vascular dementia Alzheimer's disease
CI) p HR (95% CI) p
0e4.76) <0.001 3.78 (3.29e4.34) <0.001
6e2.97) <0.001 2.36 (1.94e2.86) <0.001
7e1.95) 0.002 1.43 (1.25e1.63) <0.001
6e1.43) 0.428 1.25 (1.09e1.42) 0.001
7e4.69) <0.001 2.15 (1.88e2.45) <0.001
6e1.72) <0.001 1.45 (1.39e1.52) <0.001
1e1.69)a <0.001a 1.40 (1.34e1.46)a <0.001a
r blockers; CAD ¼ coronary artery disease; CCB ¼ calcium channel blocker;
disease; DM ¼ diabetes mellitus; HR ¼ hazard ratio; HTN ¼ hypertension.
grel, ACEI, ARB, CCB, thiazide, statins).
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patients with AD,28,29 and were recently proposed to drive
the progression of AD through different pathways.30 In a
population-based autopsy cohort study,31 people with AF
were 40e50% more likely to have gross infarcts and other
neuropathologic changes, such as amyloid angiopathy,
neuritic plaques, and neurofibrillary tangles. Although
traditional theory regards vascular factors as purely associ-
ated with vascular dementia, several recent studies have
suggested an increased risk of developing AD when exposed
to the same vascular risk factors that caused stroke and
vascular dementia.32 Concomitant with aging, cerebrovas-
cular disease and systemic vascular disorders may lead to
reduction of regional blood flow and cause cerebral hypo-
perfusion.33,34 There is a hypothesis based on experimental
studies suggesting that small vessel disease in the brain
causes chronic hypoperfusion, which may lead to pH
changes, oxidative damage, amyloid b precursor protein
expression, and subsequent aggregation of amyloid b pep-
tides.35 Moreover, the pathology of individuals with Alze-
heimer's disease had various features consistent with a
bloodebrain barrier breakdown, included thinning of the
endothelium, loss of mitochondria, and thickening of base-
ment membranes; this was thought to lead to toxic metabo-
lites crossing into the brain and increasing focal amyloid b
peptide accumulation in recent studies.36 A small burden of
cerebral ischemia caused by vascular factors may reveal the
expression of amyloid b peptides and tangles associated with
Alzeheimer's disease. The association between vascular fac-
tors and Alzeheimer's disease does not question nor negate
the traditional degenerative mechanisms of Alzeheimer's
disease. In fact, vascular brain injury could act additively or
synergistically with concomitant Alzeheimer's disease pa-
thology to produce more severe cognitive dysfunction.32
Currently known risk factors for dementia include age,
genetic susceptibility, previous stroke, hypercholesterolemia,
diabetes mellitus, hypertension, smoking, and metabolic syn-
drome.37 Although AF and dementia share many underlying
risk factors, there has been no good indicator for dementia
occurrence in AF patients. The CHADS2 score has recently
been developed as a parameter for risk prediction for AF pa-
tients, whereby it is currently widely used for future stroke
prediction and as a guide for anticoagulation prescription. In
addition, it has been reported that the CHADS2 score could be
used to predict AF recurrence after ablation, new AF occur-
rence after myocardial infarction,38 and left atrium dysfunc-
tion in CAD patients,6 offering multiple clinical applications
for risk stratification.
Our study showed that high CHADS2 score is a predictor of
poor outcome among AF patients, not only for ischemic
stroke, but also for the occurrence of dementia, providing
practical guidance in clinical use. Although this study was not
the first one to declare the association between CHADS2 score
and dementia,39 our finding suggested that the predictive value
of CHADS2 score was good for both vascular dementia and
AD. This finding implied that AF itself is an independent risk
factor for dementia, regardless of whether or not there wasclinical stroke event. CHADS2 score is a simple and exten-
sively applied tool for the evaluation of neurocardiovascular
outcomes in AF patients.
As a population-based epidemiological study, the strength
of our study is the large sample size enrolled from a
population-based dataset, enabling us to trace prospectively
the differences between the two groups. However, this study
also has several limitations. First, the diagnosis of AF and
dementia was identified using ICD-9 codes from a nationwide
database set composed of hospitalization and outpatient clinic
records. Similar methods for identifying AF using the same
database have been used in other studies.7,21,26,40 Although we
did not verify each case ourselves because of the limitations of
the database design, the diagnosis should be correct because
each event had been identified for insurance claims purposes
by qualified cardiologists or neurologist. Second, we did not
subdivide study patients according to variable forms of AF,
such as paroxysmal, persistent, and permanent AF. Some ev-
idence has been reported suggesting there is no difference
between those with paroxysmal AF and permanent AF in
complications of AF, such as stroke.41 Furthermore, there are
no separate ICD-9 codes to be used for subdivision, and the
future stroke risk of paroxysmal AF and permanent AF is
similar.7 Therefore, different types of AF were not identified
separately in our study. Third, the diagnosis of AD and
vascular dementia were also made by ICD codes. To define
dementia and its subtypes by ICD codes, and not by traditional
diagnostic criteria, would cause relatively inaccuracy of the
diagnosis. Regarding dementia other than AD and vascular
dementia, we did not enroll this population into our study
because of the small case numbers and heterogeneity of their
diagnosis. Additionally, because the dementia was identified
using ICD-9 coding from neurologists' diagnosis, it is impos-
sible to distinguish all mixed types of dementia and we did not
have primary data for further study. Finally, certain con-
founders such as body mass index, blood pressure values, and
lipid profiles were unavailable because of the limitations of the
National Health Insurance database.
In conclusion, AF is associated with an increased risk of
vascular dementia and AD. Increasing CHADS2 score could
be used as a predictor for the occurrence of dementia in pa-
tients with AF.
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